From La Jolla Institute for Immunology: 

New research published in Science magazine will guide the development of more effective COVID-19 antibody therapies and help scientists develop effective vaccines to address emerging viral variants.

​“We were able to map the geography of Spike and understand which antibodies bind to which footprints. This map provides a reference to help predict  which antibodies are still effective against SARS-CoV-2 variants of concern like the currently surging Delta variant,” says LJI Professor Erica Ollmann Saphire, Ph.D., who leads the global effort behind this research, called the Coronavirus Immunotherapeutic Consortium (CoVIC).

CoVIC is a global, academic-industry, non-profit research collaboration that brings together scientists from around the world to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2, and to streamline and accelerate the research pipeline for antibody-based therapeutics needed against SARS-CoV-2. GHR joined the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH) in supporting the global partnership, headquartered at the La Jolla Institute for Immunology (LJI). ​

Learn more here. 

In 2019, things were looking dire for Risen Christ, a dual-immersion K-8 Catholic school located in Minneapolis’ Powderhorn Park neighborhood. School administrators and members of the school board were seriously considering closing the school down. It was an all-too-common discussion at a time when many Catholic schools experiencing similar challenges were closing at an alarming rate.

Yet through creativity and community collaboration, Risen Christ has remained afloat. This case study details the story of how, offering tools for funders that are considering helping struggling institutions pull themselves out from under the burden of debt.

Read the full case study here: